CO:11:2 | Systemic lupus erythematosus with major neuropsychiatric involvement treated with anifrolumab: literature review and a case report
Background. Anifrolumab is a biologic agent approved for the treatment of Systemic Lupus Erythematosus (SLE). Clinical trials evaluating its efficacy (TULIP-1 and TULIP-2) excluded patients with active neuropsychiatric manifestations (NPSLE). The aim of this study was to review the published cases...
में बचाया:
| मुख्य लेखक: | |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
PAGEPress Publications
2025-11-01
|
| श्रृंखला: | Reumatismo |
| विषय: | |
| ऑनलाइन पहुंच: | https://www.reumatismo.org/reuma/article/view/2120 |
| टैग: |
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|